Liraglutide Protects Kidneys in Diabetic Rats by Reshaping Gut Bacteria and Reducing Harmful Metabolite
Liraglutide ameliorated diabetic kidney disease in rats by modifying gut microbiota composition and increasing L-5-Oxoproline levels, which reduced harmful fat accumulation in kidney tubular cells.
Quick Facts
What This Study Found
Liraglutide improved gut microbiota diversity (increased Simpson index, P=0.035), boosted beneficial bacteria like Clostridium and Oscillospira, increased serum L-5-Oxoproline, and reduced ectopic lipid deposition in kidney tubules through SREBP1/FAS pathway suppression.
Key Numbers
Liraglutide decreased serum L-5-Oxoproline levels and reduced ectopic lipid deposition in renal tubules of diabetic rats.
How They Did This
Diabetic kidney disease rat model (Sprague-Dawley rats on high-fat diet + streptozotocin + uninephrectomy) treated with liraglutide 0.4 mg/kg/day. Multi-omics analysis of gut microbiome, serum metabolites, and kidney pathology. In vitro validation with HK-2 kidney cells exposed to high glucose/palmitate and L-5-Oxoproline.
Why This Research Matters
Diabetic kidney disease is the leading cause of kidney failure worldwide. This study reveals a novel gut-kidney axis mechanism for liraglutide's renoprotective effects, opening potential new therapeutic strategies targeting gut microbiota and metabolites.
The Bigger Picture
The gut microbiome-metabolites-kidney axis is emerging as a key player in diabetic complications. Liraglutide's ability to reshape gut bacteria and produce beneficial metabolites suggests GLP-1 drugs may protect organs through pathways entirely separate from their glucose-lowering effects.
What This Study Doesn't Tell Us
Animal study — gut microbiome and metabolite responses may differ in humans. The DKD rat model (high-fat diet + STZ + nephrectomy) is artificial. Specific bacterial strains responsible for 5-OP production were not definitively identified. No human clinical validation.
Questions This Raises
- ?Could direct supplementation with L-5-Oxoproline protect against diabetic kidney disease without GLP-1 drugs?
- ?Do newer GLP-1 agonists like semaglutide produce similar gut microbiome changes and kidney protection?
- ?Would probiotic supplementation with the beneficial bacteria identified (Clostridium, Oscillospira) enhance liraglutide's kidney-protective effects?
Trust & Context
- Key Stat:
- Gut-kidney axis Liraglutide reshapes gut bacteria to produce L-5-Oxoproline, which independently reduces harmful fat accumulation in kidney cells
- Evidence Grade:
- Preliminary evidence — animal study with in vitro validation. Novel mechanistic finding but requires human clinical confirmation.
- Study Age:
- Published in 2024, contributing to the growing understanding of GLP-1 agonist effects on the gut microbiome-kidney axis.
- Original Title:
- Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline.
- Published In:
- European journal of pharmacology, 983, 176905 (2024)
- Authors:
- Yi, Bo, Su, Ke, Cai, Yu-Li, Chen, Xiao-Ling, Bao, Yan, Wen, Zhong-Yuan
- Database ID:
- RPEP-09603
Evidence Hierarchy
Frequently Asked Questions
How does liraglutide protect kidneys through the gut?
Liraglutide changes the composition of gut bacteria, increasing types that produce a metabolite called L-5-Oxoproline. This metabolite travels through the blood to the kidneys, where it prevents harmful fat from building up in kidney cells by turning off fat-production genes.
Could probiotics provide similar kidney protection to liraglutide?
The study identified specific beneficial bacteria (Clostridium, Oscillospira) that increased with liraglutide treatment and correlated with kidney protection. While targeted probiotics haven't been tested for this purpose, the findings suggest it could be worth exploring.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09603APA
Yi, Bo; Su, Ke; Cai, Yu-Li; Chen, Xiao-Ling; Bao, Yan; Wen, Zhong-Yuan. (2024). Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline.. European journal of pharmacology, 983, 176905. https://doi.org/10.1016/j.ejphar.2024.176905
MLA
Yi, Bo, et al. "Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline.." European journal of pharmacology, 2024. https://doi.org/10.1016/j.ejphar.2024.176905
RethinkPeptides
RethinkPeptides Research Database. "Liraglutide ameliorates diabetic kidney disease by modulatin..." RPEP-09603. Retrieved from https://rethinkpeptides.com/research/yi-2024-liraglutide-ameliorates-diabetic-kidney
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.